5 Drugs Stocks Driving The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 161 points (1.0%) at 15,537 as of Monday, Sept. 16, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 2,425 issues advancing vs. 535 declining with 80 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.9%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 1.9%, Valeant Pharmaceuticals International ( VRX), up 1.7%, Novo Nordisk A/S ( NVO), up 1.7%, AstraZeneca ( AZN), up 1.6% and Eli Lilly and Company ( LLY), up 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Biogen Idec ( BIIB) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biogen Idec is up $5.00 (2.1%) to $239.71 on average volume. Thus far, 508,140 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $236.31-$240.20 after having opened the day at $238.03 as compared to the previous trading day's close of $234.71.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $55.6 billion and is part of the health care sector. Shares are up 59.9% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire